Minerva Surgical, Inc. (UTRS)

Market Cap	888.00 -100.0%
Revenue (ttm)	51.69M +3.1%
Net Income	-33.45M
EPS	-5.38
Shares Out	8.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150
Average Volume	1,111
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	83.94
RSI	19.96
Earnings Date	Mar 20, 2026

About Minerva Surgical

Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 174
• Stock Exchange: OTCMKTS
• Ticker Symbol: UTRS

Financial Performance

In 2022, Minerva Surgical's revenue was $50.29 million, a decrease of -3.47% compared to the previous year's $52.10 million. Losses were -$34.11 million, 58.9% more than in 2021.